Real-World Adherence to Oral Therapies in IgA Nephropathy (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0663; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Five non-mutually exclusive cohorts were defined by oral therapy class: Budesonide, Sparsentan, Iptacopan, ACEi/ARBs, and SGLT2is. Conclusion Medication adherence to oral therapies in IgAN was suboptimal in real-world settings, approximately half the patients met the adherence threshold. Lower adherence was associated with higher HCRU, highlighting an unmet need for alternative options to improve adherence."
Adherence • Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular • Chronic Kidney Disease • Glomerulonephritis • Hypertension • IgA Nephropathy • Inflammation • Rare Diseases • Renal Disease
|
|
Yan Wang; Menelaos Konstantinidis; Preeti Joshi
|